{
    "id": 27012,
    "fullName": "CRKL over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CRKL over exp indicates an over expression of the Crkl protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1399,
        "geneSymbol": "CRKL",
        "terms": [
            "CRKL"
        ]
    },
    "variant": "over exp",
    "createDate": "09/20/2017",
    "updateDate": "01/23/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12013,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment of Iressa (gefitinib) and Pictilisib (GDC-0941) inhibited Pi3k activation, resulting in growth inhibition of non-small cell lung carcinoma cells harboring EGFR E746_A750del and overexpressing Crkl in culture (PMID: 22586683).",
            "molecularProfile": {
                "id": 28382,
                "profileName": "CRKL over exp EGFR E746_A750del"
            },
            "therapy": {
                "id": 6228,
                "therapyName": "Gefitinib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9959,
                    "pubMedId": 22586683,
                    "title": "Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12014,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment of Iressa (gefitinib) and LY294002 inhibited Pi3k activation, resulting in growth inhibition of non-small cell lung carcinoma cells harboring EGFR E746_A750del and overexpressing Crkl in culture (PMID: 22586683).",
            "molecularProfile": {
                "id": 28382,
                "profileName": "CRKL over exp EGFR E746_A750del"
            },
            "therapy": {
                "id": 6229,
                "therapyName": "Gefitinib + LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9959,
                    "pubMedId": 22586683,
                    "title": "Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12010,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment of Iressa (gefitinib) and PHA-665752 failed to inhibit proliferation of non-small cell lung carcinoma cells harboring EGFR E746_A750del and overexpressing Crkl in culture (PMID: 22586683).",
            "molecularProfile": {
                "id": 28382,
                "profileName": "CRKL over exp EGFR E746_A750del"
            },
            "therapy": {
                "id": 5094,
                "therapyName": "Gefitinib + PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9959,
                    "pubMedId": 22586683,
                    "title": "Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12008,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Crkl in non-small cell lung carcinoma cells harboring EGFR E746_A750del resulted in decreased sensitivity to Sprycel (dasatinib) in culture (PMID: 22586683).",
            "molecularProfile": {
                "id": 28382,
                "profileName": "CRKL over exp EGFR E746_A750del"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9959,
                    "pubMedId": 22586683,
                    "title": "Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586683"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12003,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Crkl in non-small cell lung carcinoma cells harboring EGFR E746_A750del resulted in resistance to Iressa (gefitinib) in culture (PMID: 22586683).",
            "molecularProfile": {
                "id": 28382,
                "profileName": "CRKL over exp EGFR E746_A750del"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9959,
                    "pubMedId": 22586683,
                    "title": "Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12009,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Crkl in non-small cell lung carcinoma cells harboring EGFR E746_A750del resulted in decreased sensitivity to the combination treatment of Sprycel (dasatinib) and Iressa (gefitinib) in culture (PMID: 22586683).",
            "molecularProfile": {
                "id": 28382,
                "profileName": "CRKL over exp EGFR E746_A750del"
            },
            "therapy": {
                "id": 6226,
                "therapyName": "Dasatinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9959,
                    "pubMedId": 22586683,
                    "title": "Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22586683"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28381,
            "profileName": "CRKL over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28382,
            "profileName": "CRKL over exp EGFR E746_A750del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28383,
            "profileName": "CRKL over exp EGFR mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}